20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York
GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that President and Chief Executive Officer Jonathan Cohen and Chief Financial Officer Alan Bergman will participate in the Maxim Growth Summit 2026, being held October 13 and 14, 2026 at the Hard Rock Hotel New York. The Summit’s healthcare program takes place Wednesday, October 14.
Mr. Cohen and Mr. Bergman will hold one-on-one meetings with institutional investors at the Summit and in additional meetings scheduled in New York that week.
Maxim Growth Summit 2026
Dates: October 13 and 14, 2026; healthcare program Wednesday, October 14
Location: Hard Rock Hotel New York, 159 West 48th Street, New York, NY 10036
Format: One-on-one investor meetings
Attendees: President and Chief Executive Officer Jonathan Cohen; Chief Financial Officer Alan Bergman
Conference Website: Click here
To schedule a one-on-one meeting with management at the Maxim Growth Summit or in New York that week, please contact your Maxim Group representative, email AIDX@mzgroup.us, or call Chris Tyson at (949) 491-8235.
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s affordable, accurate, accessible tests can be conveniently utilized at home using new, upper-arm capillary collection devices that avoid painful needles. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
For more information visit https://2020biolabs.com.
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
6 ETFs To Diversify Away From AI
Why This Vanguard ETF Is One of the Best
The Best AI Stocks to Buy Now
United States